Acoustic Neuroma, Neurofibromatosis 2, Vestibular Schwannoma
Conditions
Brief summary
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
Detailed description
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients. In the Randomized Treatment Phase, patients aged 12 years or older with VSs will be identified and recruited into one of two randomized groups who receive either 1) 325 mg aspirin twice daily (81 mg aspirin twice daily for pediatric patients \<50 kg); or 2) a placebo. Patients will stay on aspirin/placebo as long as there is no more than 20% increase in VS volume. At tumor progression, patients will enter the Open Label Follow Up Phase. Patients who progress on placebo will be given the option to receive unblinded aspirin and will be followed until further progression, receiving a definitive treatment (e.g, surgery or radiation), or 42 months post-baseline, whichever occurs first. Patients who progress on aspirin (either blinded or unblinded) will be taken off study drug and followed until they receive a definitive treatment (e.g., surgery or radiation) or reach 42 months post-baseline, whichever comes first.
Interventions
DRUGAspirin
Twice daily aspirin
DRUGPlacebo
Twice daily placebo
Sponsors
United States Department of Defense
Massachusetts Eye and Ear Infirmary
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
In the Randomized Treatment Phase, patients aged 12 years or older with VSs will be identified and recruited into one of two randomized groups who receive either 1) 325 mg aspirin twice daily (81 mg aspirin twice daily for pediatric patients \<50 kg); or 2) a placebo. Patients will stay on aspirin/placebo as long as there is no more than 20% increase in VS volume. At tumor progression, patients will enter the Open Label Follow Up Phase. Patients who progress on placebo will receive unblinded aspirin. Patients who progress on aspirin (either blinded or unblinded) will be taken off study drug and followed. All patients will be followed for at least 3.5 years after randomization.
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic). * Age≥12 years. * Ability to provide informed consent.Pediatric patients must provide assent in addition to their parents'/guardians' consent. Adult patients who cannot consent for themselves will not be eligible to participate in this study. * Ability to swallow tablets.
Exclusion criteria
* Inability to perform volumetric measurements of vestibular schwannoma(s). * Inability to tolerate MRI with contrast. * Daily use of aspirin within the last two months. Occasional use of aspirin for pain relief is not exclusionary. * Known allergy to aspirin. * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin. * Pregnant or lactating women. * Patients with serious medical illnesses (e.g. severe asthma) that in the option of the investigator could prevent participation in the trial. * Active bleeding diathesis. * Hydrocephalus from brainstem compression. * Febrile illness or flu-like illness in children and adolescents less than 18 years of age.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Progression, or around 3.5 years | Progression Free Survival (PFS) is the length of time from start of study treatment to tumor growth of more than 20%. |
Countries
United States
Outcome results
None listed